fashion -WSS

fashion

author：comprehensive 2025-09-14 14:42:32 - browse：1971

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

hotspot

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

Three issues to watch in global health in 2024

With Roe v Wade overturned, abortion providers work to adapt

Biotech reporter’s notebook: A sunnier mood at JPM 2024

DeSantis can now import cheaper drugs. But will Biden get credit?

Experts study whether long Covid risk adds up with each reinfection

focus

fashion

entertainment

Supreme Court strikes down use of affirmative action

New oral drug delivery patch is modeled after octopus tentacles

Duchenne breakthrough therapy leaves behind pioneering families

DeSantis can now import cheaper drugs. But will Biden get credit?

United colonoscopy coverage change 'may cost lives,' doctors say

Generative AI mines health records to identify patients’ social needs

Novavax promises a turnaround & Lilly roils the obesity market

The SUPPORT Act is critical to fighting the opioid crisis

Drug repurposing or repositioning? The language matters

JPM 2024: Verve Therapeutics looks to mainstream genome editing

hotspot

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Study points to new risk in gene therapy death of Terry Horgan

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Will an HIV vaccine ever be a reality?

GSK to buy asthma

Wikipedia

explore

hotspot

focus